TrialJournal for immunotherapy of cancer2025

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Jean-Sébastien Frenel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.